Is Karyopharm Therapeutics, Inc. overvalued or undervalued?

As of 15 March 2018, Karyopharm Therapeutics, Inc. has moved from a grade of does not qualify to risky, indicating increased concerns about its valuation. The company appears to be overvalued given its negative valuation metrics, including a Price to Book Value of -0.19, an EV to EBIT of -1.25, and an EV to EBITDA of -1.26. Compared to peers, Karyopharm's EV to EBITDA ratio of -1.6265 is significantly worse than XOMA Corp.'s -22.9484 and Zevra Therapeutics, Inc.'s 7.4373, highlighting its relative weakness in the industry.
The stock's performance has been notably poor, with a year-to-date return of -43.52% compared to the S&P 500's 12.22%, and a staggering decline of -97.66% over the past five years, while the S&P 500 has gained 96.61%. This stark contrast in returns further reinforces the notion that Karyopharm is overvalued in its current state.